QNCX
Quince Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-2.68 EPS
$0.94
▼ -3.34%$0.94▼ -92.85%
over 1Y
L $0.80EODHDH $44.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-3.3%
1W+1.7%
1M-18.0%
3M+7.2%
YTD-96.9%
1Y-92.9%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Sell
Conservative balance sheet (liabilities/equity -3.62x).
Liabilities / equity -3.62x · latest
Quince Therapeutics, Inc. shows limited reported revenue.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$90.3M | -$52.0M | -$34.6M | -$57.3M | -$58.1M |
| Net income | -$89.9M | -$51.7M | -$31.4M | -$56.8M | -$84.0M |
| Diluted EPS | -$3.03 | -$1.54 | -$0.84 | -$1.31 | -$1.68 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$166M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-54.6%
FCF yield-27.2%
Quality & risk
ROIC (est.)—
Free cash flow-$41.8M
Total debt$18.0M
Net cash-$12.2M
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+270.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-K/APeriod ending 2026-06-262026-06-26open ↗8-KPeriod ending 2026-06-262026-06-26open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-05-182026-06-11open ↗3Period ending 2026-05-182026-06-11open ↗8-KPeriod ending 2026-06-112026-06-11open ↗DFiling2026-06-11open ↗DFiling2026-06-11open ↗SCHEDULE 13GFiling2026-06-10open ↗8-KPeriod ending 2026-05-202026-05-21open ↗8-K/APeriod ending 2026-05-172026-05-18open ↗
Frequently asked
- Is Quince Therapeutics, Inc. (QNCX) a buy?
- QNCX currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -3.62x).
- What is Quince Therapeutics, Inc.'s quality score?
- QNCX scores 18.999999999999996/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001662774, latest 10-Q filed 2026-05-11) · EODHD · as of 6/26/2026, 1:20:16 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.